Cytek Biosciences, Inc. (CTKB) Misses Q3 EPS by 1c, Beats on Revenue

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $51.03 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Pfizer executive says China now leads Europe in drug innovation
• Doncasters Group guiding IPO pricing at top of range - Bloomberg